GlassScriptPhysician profile
Vikram Prasanna
NPI 1679735252
$7,087.37
in general payments reported to CMS, 2019-2025
36 companies · $888 in 2025
The $888 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,154 · 2020: $488 · 2021: $634 · 2022: $1,482 · 2023: $716 · 2024: $726 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,329.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $835.67 | 2019-2024 | Impella |
| Abbott Laboratories | $807.72 | 2019-2024 | Aveir, Jot Dx, Mitraclip |
| Cardiovascular Systems INC. | $739.35 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $644.46 | 2019-2025 | |
| Amgen INC. | $432.45 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $352.00 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $293.81 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $271.25 | 2023-2025 | Verquvo |
| Boston Scientific Corporation | $246.43 | 2019-2025 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $227.84 | 2019-2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $221.20 | 2019-2025 | Uptravi, Opsumit |
| Zoll Respicardia, INC. | $192.81 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $184.60 | 2022-2024 | Brilinta, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.26 | 2022-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $175.78 | 2019-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $164.59 | 2019-2025 | Lifevest |
| Amarin Pharma, INC. | $149.20 | 2019-2022 | |
| Scpharmaceuticals INC. | $144.30 | 2023-2025 | |
| Atricure, INC. | $134.46 | 2022 | |
| Novo Nordisk INC | $129.45 | 2022-2025 | Wegovy |
| Medtronic Vascular, INC. | $125.00 | 2020 | |
| Angiodynamics, INC. | $102.51 | 2022 | |
| Cvrx, INC. | $34.75 | 2025 | Barostim Neo System |
| Regeneron Healthcare Solutions, INC. | $32.79 | 2019 | |
| Portola Pharmaceuticals, LLC | $28.87 | 2019 | |
| Recor Medical INC | $28.00 | 2025 | Paradise Ultrasound Renal Denervation System |
| Daiichi Sankyo INC. | $25.00 | 2024 | Injectafer |
| Livanova USA, INC. | $24.82 | 2020 | |
| Penumbra, INC. | $24.40 | 2023 | Indigo System |
| Esperion Therapeutics, INC. | $24.09 | 2021 | |
| Heartflow, INC. | $23.42 | 2025 | |
| Terumo Medical Corporation | $19.34 | 2023 | Glidesheath Slender |
| Edwards Lifesciences Corporation | $17.40 | 2019 | |
| Teleflex LLC | $16.31 | 2023 | Guideliner |
| Smith+Nephew, INC. | $16.26 | 2024 | Pico 7 |
| Genzyme Corporation | $15.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Prasanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.